Physician

Abbas Rabiei, MD

According to 2025 Medicare claims, Abbas Rabiei, MD (NPI: 1447242268) practices internal medicine in the West Palm Beach-Boca Raton-Delray Beach, FL market, with the plurality of this provider's patient population coming from Palm Beach, FL. This provider's primary affiliated billing organization is COASTAL NEPHROLOGY & HYPERTENSION CENTER, PA (NPI: 1881686608; TIN: 201054138) and primary practice location at 33458-2791. Rabiei is affiliated with the PBACO Holding, LLC (ACO ID: A1001) and Caravan Health ACO 50 LLC (ACO ID: A5160), participating under the MSSP model.

Rabiei's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 990 traditional Medicare patients, billed 8,710 HCPCS/CPT codes, and received $800,316 in Medicare payments. The top billing code was 99222 (Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes). Part D data shows 7,210 prescription claims across 772 beneficiaries totaling $942,817 in drug costs, led by Ozempic (Semaglutide). DME data shows 290 claims. Open Payments data shows 81 records totaling $2,679. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved from a higher plateau to a lower plateau, from $1,239,299 to $942,817. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $5,566 to $2,514.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	713	6,914	$576,829
2016	732	8,946	$721,841
2017	758	10,211	$790,913
2018	731	8,442	$701,478
2019	707	7,755	$704,928
2020	704	7,041	$648,033
2021	765	7,604	$728,385
2022	788	6,858	$644,702
2023	846	7,207	$704,915
2024	990	8,710	$800,316

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	422	8,078	$1,239,299
2016	434	8,534	$1,021,519
2017	420	7,179	$898,663
2018	459	5,698	$556,810
2019	449	4,799	$482,209
2020	489	5,361	$536,202
2021	498	5,338	$465,900
2022	551	5,491	$511,684
2023	618	6,012	$697,186
2024	772	7,210	$942,817

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	15	392	$71,510
2016	33	197	$7,180
2017	15	136	$3,726
2018	N/R	80	$2,819
2019	N/R	128	$7,939
2020	12	301	$27,013
2021	11	223	$11,185
2022	N/R	249	$19,673
2023	N/R	235	$4,767
2024	N/R	290	$5,349

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	324	507	$103
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	321	1,670	$94
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	654	1,827	$93
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	448	779	$65
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	276	2,189	$63

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ozempic	Semaglutide	109	4,240	$114,627
Kerendia	Finerenone	104	5,524	$111,363
Farxiga	Dapagliflozin Propanediol	130	5,940	$109,683
Xphozah	Tenapanor Hcl	22	990	$93,223
Eliquis	Apixaban	99	4,673	$90,621

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7518	Mycophenolic acid, oral, 180 mg	N	N/R	22	$1,480
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	77	$1,264
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	86	$990
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	56	$960
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	38	$649

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	81	$2,679	CALLIDITAS THERAPEUTICS US INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Abbas Rabiei, MD?

Tedicare shows public-source Medicare data for Abbas Rabiei, MD (NPI 1447242268), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Abbas Rabiei, MD have ACO affiliation data?

Abbas Rabiei, MD is shown with ACO affiliation data for PBACO Holding, LLC (MSSP, ACO ID A1001) and Caravan Health ACO 50 LLC (MSSP, ACO ID A5160).

What billing organization is linked to Abbas Rabiei, MD?

Abbas Rabiei, MD is linked to COASTAL NEPHROLOGY & HYPERTENSION CENTER, PA (billing NPI 1881686608) in the available physician profile data.

Does Abbas Rabiei, MD have Open Payments data?

Abbas Rabiei, MD has 81 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.